Endoscopic resection is more effective than biopsy or EUS to detect residual rectal neuroendocrine tumor
- PMID: 33403229
- PMCID: PMC7775810
- DOI: 10.1055/a-1300-1017
Endoscopic resection is more effective than biopsy or EUS to detect residual rectal neuroendocrine tumor
Abstract
Background and study aims Rectal neuroendocrine tumors (NETs) are often discovered incidentally and may be misidentified as adenomatous polyps. This can result in a partial resection at the index procedure, and lesions are often referred for staging or evaluation for residual disease at the resection site. The aim of this study was to identify the ideal method to confirm complete excision of small rectal NETs. Patients and methods Data from patients with a previously resected rectal NET referred for follow-up endoscopy or endoscopic ultrasound (EUS) were retrospectively reviewed. Univariate analysis was performed on categorical data using the Chi-squared test. Results Forty-nine patients with rectal NETs were identified by pathology specimens. Of those, 39 underwent follow-up endoscopy or EUS and were included. Baseline characteristics included gender (71 % F, 29 % M), age (57.2 ± 13.4 yrs) lesion size (7.3 ± 4.2 mm) and location. The prior resection site was identified in 37/39 patients who underwent tissue sampling. Residual NET was found histologically in 14/37 lesions. All residual disease was found during salvage endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) and 43 % had a normal-appearing scar. Every patient undergoing EUS had an unremarkable exam. Initial cold biopsy polypectomy ( P = 0.006), visible lesions ( P = 0.001) and EMR/ESD of the prior resection site ( P = 0.01) correlated with residual NET. Conclusions Localized rectal NETs may be incompletely removed with standard polypectomy. If an advanced resection is not performed initially, repeat endoscopy with salvage EMR or ESD of the scar should be considered. For small rectal NETs, biopsy may miss residual disease when there is no visible lesion and EUS appears to have no benefit.
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Conflict of interest statement
Competing interests The authors declare that they have no conflict of interest.
Figures
Similar articles
-
Cap-Assisted Endoscopic Mucosal Resection for Rectal Neuroendocrine Tumors: An Effective Option.GE Port J Gastroenterol. 2022 Aug 26;30(2):107-114. doi: 10.1159/000525964. eCollection 2023 Mar. GE Port J Gastroenterol. 2022. PMID: 37008522 Free PMC article.
-
Advantage of endoscopic mucosal resection with a cap for rectal neuroendocrine tumors.World J Gastroenterol. 2015 Aug 21;21(31):9387-93. doi: 10.3748/wjg.v21.i31.9387. World J Gastroenterol. 2015. PMID: 26309365 Free PMC article.
-
Risk factors for residual tumors in histologically incompletely resected rectal neuroendocrine tumors.Dig Liver Dis. 2025 Jul;57(7):1473-1480. doi: 10.1016/j.dld.2025.03.023. Epub 2025 Apr 18. Dig Liver Dis. 2025. PMID: 40253226
-
Current status of the role of endoscopy in evaluation and management of gastrointestinal and pancreatic neuroendocrine tumors.Indian J Gastroenterol. 2023 Apr;42(2):158-172. doi: 10.1007/s12664-023-01362-8. Epub 2023 May 2. Indian J Gastroenterol. 2023. PMID: 37129761 Review.
-
Diagnosis and Management of Rectal Neuroendocrine Tumors.Clin Endosc. 2017 Nov;50(6):530-536. doi: 10.5946/ce.2017.134. Epub 2017 Nov 30. Clin Endosc. 2017. PMID: 29207857 Free PMC article. Review.
Cited by
-
An Update on the Management of Rectal Neuroendocrine Neoplasms.Curr Treat Options Oncol. 2024 Nov;25(11):1461-1470. doi: 10.1007/s11864-024-01267-4. Epub 2024 Oct 30. Curr Treat Options Oncol. 2024. PMID: 39476215 Free PMC article. Review.
-
The role of endoscopic ultrasonography for diagnosis of residual rectal neuroendocrine tumor.Surg Endosc. 2024 Aug;38(8):4260-4267. doi: 10.1007/s00464-024-10963-z. Epub 2024 Jun 12. Surg Endosc. 2024. PMID: 38866946
-
Optimising Outcomes and Surveillance Strategies of Rectal Neuroendocrine Neoplasms.Cancers (Basel). 2023 May 15;15(10):2766. doi: 10.3390/cancers15102766. Cancers (Basel). 2023. PMID: 37345103 Free PMC article. Review.
-
Outcome of Endoscopic Resection of Rectal Neuroendocrine Tumors ≤ 10 mm.Diagnostics (Basel). 2024 Jul 11;14(14):1484. doi: 10.3390/diagnostics14141484. Diagnostics (Basel). 2024. PMID: 39061621 Free PMC article.
-
Prognosis of incompletely resected small rectal neuroendocrine tumor using endoscope without additional treatment.BMC Gastroenterol. 2022 Jun 9;22(1):293. doi: 10.1186/s12876-022-02365-z. BMC Gastroenterol. 2022. PMID: 35681149 Free PMC article.
References
-
- Anthony L B, Strosberg J R, Klimstra D S et al.The NANETS Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors (NETs): Well-Differentiated NETs of the Distal Colon and Rectum. Pancreas. 2010;39:767–774. - PubMed
-
- Caplin M, Sundin A, Nillson O et al.ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology. 2012;95:88–97. - PubMed
-
- Yao J C, Hassan M, Phan A et al.One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–3072. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous